Citation: Vj. Watts et al., Dopamine D-2 receptor-induced heterologous sensitization of adenylyl cyclase requires G alpha(s): Characterization G alpha(s)-insensitive mutants of adenylyl cyclase V, MOLEC PHARM, 60(6), 2001, pp. 1168-1172
Authors:
Neve, KA
Cumbay, MG
Thompson, KR
Yang, R
Buck, DC
Watts, VJ
Durand, CJ
Teeter, MM
Citation: Ka. Neve et al., Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D-2 receptor, MOLEC PHARM, 60(2), 2001, pp. 373-381
Authors:
Schutzer, WE
Watts, VJ
Chapman, J
Cumbay, MG
Neve, KA
Neve, RL
Mader, SL
Citation: We. Schutzer et al., Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity, CLIN EXP PH, 27(1-2), 2000, pp. 9-13
Authors:
Wilcox, RE
Huang, WH
Brusniak, MYK
Wilcox, DM
Pearlman, RS
Teeter, MM
DuRand, CJ
Wiens, BL
Neve, KA
Citation: Re. Wilcox et al., CoMFA-based prediction of agonist affinities at recombinant wild type versus serine to alanine point mutated D2 dopamine receptors, J MED CHEM, 43(16), 2000, pp. 3005-3019
Authors:
Watts, VJ
Vu, MN
Wiens, BL
Jovanovic, V
Van Tol, HHM
Neve, KA
Citation: Vj. Watts et al., Short and long-term heterologous sensitization of adenylate cyclase by D-4dopamine receptors, PSYCHOPHAR, 141(1), 1999, pp. 83-92
Authors:
Eshleman, AJ
Carmolli, M
Cumbay, M
Martens, CR
Neve, KA
Janowsky, A
Citation: Aj. Eshleman et al., Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type, J PHARM EXP, 289(2), 1999, pp. 877-885